Cardiovascular changes in cirrhosis: Pathogenesis and clinical implications

Saudi Journal of Gastroenterology

Volumn 16, Issue 3, 2010, Pages 145-153

  Al Hamoudi, Waleed K ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cirrhosis; cirrhotic cardiomyopathy; hyperdynamic circulation; liver transplantation

Indexed keywords

ASCITES; BACTERIAL PERITONITIS; CARDIOVASCULAR DISEASE; ESOPHAGUS VARICES; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOGENESIS; PORTAL HYPERTENSION; PROGNOSIS; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; LUNG CIRCULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SPLANCHNIC BLOOD FLOW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VASODILATATION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; PULMONARY CIRCULATION; SPLANCHNIC CIRCULATION; VASODILATION;

EID: 77954804758     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.65181     Document Type: Review

References (118)

1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953;32:1025-1033
2. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences. Hepatology 1994;20:1359-1363
3. Ma Z, Lee SS. Cirrhotic cardiomyopathy: Getting to the heart of the matter. Hepatology 1996;24:451-459
4. Müller S, Henriksen JH. Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
5. Wong F, Sniderman K, Blendis L. The renal sympathetic and renin- angiotensin response to lower body negative pressure in well- compensated cirrhosis. Gastroenterology 1998;115:397-405.
6. Muller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int 2008;2:416-428
7. Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am 2009;93:855-869
8. Chang SW, Ohara N. Chronic biliary obstruction induces pulmonary intravascular phagocytosis and endotoxin sensitivity in rats. J Clin Invest 1994;94:2009-2019
9. Carter EP, Hartsfield CL, Miyazono M, Jakkula M, Morris KG Jr, McMurtry IF. Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol 2002;283:L346-53.
10. Sztrymf B, Rabiller A, Nunes H, Savale L, Lebrec D, Le Pape A, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J 2004;23:752-758
11. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 1987;4:8-14.
12. Garcia-Tsao G. Bacterial translocation: Cause or consequence of decompensation in cirrhosis? J Hepatol 2001;34:150-155
13. Odeh M, Sabo E, Srugo I, Oliven A. Serum levels of tumor necrosis factor-alpha correlate with severity of hepatic encephalopathy due to chronic liver failure. Liver Int 2004;24:110-116
14. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: A major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-767
15. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996;23:1616-1621
16. Niederberger M, Martin PY, Gines P, Morris K, Tsai P, Xu DL, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995;109:1624-1630
17. Ferguson JW, Dover AR, Chia S, Cruden NL, Hayes PC, Newby DE. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 2006;55:542-546
18. Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999;276:G1043-51.
19. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanism of extrahepatic vasodilatation in portal hypertension. Gut 2008;57;1300-1314
20. Moezi L, Gaskari SA, Lee SS. Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol 2008;295:G649-53.
21. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-832
22. Lee SS, Sharkey KA. Capsaicin treatment blocks development of hyperkinetic circulation in portal hypertensive and cirrhotic rats. Am J Physiol 1993;264:G868-73.
23. Song D, Liu H, Sharkey KA, Lee SS. Hyperdynamic circulation in portal- hypertensive rats is dependent on central c-fos gene expression. Hepatology 2002;35:159-166
24. Li Y, Song D, Zhang Y, Lee SS. Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats. Gut 2003;52:293-299
25. Liu H, Schuelert N, McDougall JJ, Lee SS. Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut 2008;57:966-973
26. Bayley TJ, Segel N, Bishop JM. The circulatory changes in patients with cirrhosis of the liver at rest and during exersize. Clin Sci 1964;26:227-235
27. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Circulation 1974;49:755-760
28. Lee SS, MartyJ, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial P-adrenergic receptors in cirrhotic rats. Hepatology 1990;12:481-485
29. Ingles AC, Hernandez I, Garcia-Estan J, Quesada T, Carbonell LF. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol 1991;260:H1912-7.
30. Fleming JW, Wisler PL, Watanabe AM. Signal transduction by G-protiens in cardiac tissues. Circulation 1992;85:420-433
31. Gilman AG. G-protiens: Transducers of receptor-generated signals. Annu Rev Biochem 1987;56:615-649
32. Reuter H. Calcium channel modulation by neurotransmitters, enzymes, and drugs. Nature 1983;301:569-574
33. Ma Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac beta- adrenergic receptor function in cirrhotic rats. Am J Physiol 1994;267:G87-93.
34. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta -adrenergic receptor signalling in rats with cirrhoticcardiomyopathy. J Hepatol 1997;26:904-912
35. Jaue DN, Ma Z, Lee SS. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 1997;25:1361-1365
36. Le Grimellec C, Friedlander G, el Yandouzi EH, Zlatkine P, Giocondi MC. Membrane fluidity and transport properties in epithelia. Kidney Int 1992;42:825-836
37. Moreau R, Komeichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate- sensetive potassium channels in rats with cirrhosis. Gastroenterology 1994;106:1016-1023
38. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995;22:370-376
39. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997;273:G537-44.
40. Smith TW, Balligand JL, Kaye DM, Wiviott SD, Simmons WW, Han X, et al. The role of the NO pathway in the control of cardiac function. J Card Fail 1996;2:S141-7.
41. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: Pathogenic mechanisms. World J Gastroenterol 2006;12:837-842
42. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A 1993;90:347-351
43. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000;118:937-944
44. Tohse N, Nakaya H, Takeda Y, Kanno M. Cyclic GMP-mediated inhibition of L-type Ca2+ channel activity by human natriuretic peptide in rabbit heart cells. Br J Pharmacol 1995;114:1076-1082
45. Liu H, Song D, Lee SS. Role of heme oxygenase - carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol Gastrointest Liver Physiol 2001;280:G68-74.
46. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003;41:657-664
47. Ford WR, Honan SA, White R, Hiley CR. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 2002;135:1191-1198
48. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005;146:315-323
49. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water-retention in cirrhosis. Hepatology 1988;8:1151-1157
50. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986;6:287-298
51. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008;28:81-95.
52. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999;97:259-267
53. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218
54. Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: A manifestation of cirrhotic cardiomyopathy?. Hepatology 2003;38:1089-1091
55. Villanueva C, Aracil C, Colomo A, Hernandez-Gea V, Lopez-Balaguer JM, Alvarez-Urturi C, et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis ofvariceal bleeding. Gastroenterology 2009;137:119-128
56. La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, Garcia-Pagan JC, et al. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol 2009;51:279-287
57. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009;50:923-928
58. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/ Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-748
59. Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsen the hyperdynamic circulatory state of the cirrhotic patient: Preliminary report of a prospective study. Hepatology 1994;19:129-132
60. Rodriguez-Laiz JM, Banares R, Echenagusia A, Casado M, Camunez F, Perez-Roldan F, et al. Effects oftransjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results. Dig Dis Sci 1995;40:2121-2127
61. Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villarreal L, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral and hemodynamic parameters. Hepatology 1995;21:986-994
62. Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: Short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology 1999;29:632-639
63. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002;97:142-148
64. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009;104:2458-2466
65. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut 2007;56:869-875
66. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000;6:S44-52.
67. Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation 2009;87:763-770
68. Ripoll C, Catalina MV, Yotti R, Olmedilla L, Perez-Pena J, Lo Iacono O, et al. Cardiac dysfunction during liver transplantation: Incidence and preoperative predictors. Transplantation 2008;85:1766-1772
69. Marquez J, Martin D, Virji MA, Kang YG, Warty VS, Shaw B Jr, et al. Cardiovascular depression secondary to citrate intoxication during orthotropic liver transplantation in man. Anesthesiology 1986;65:457-461
70. Dec GW, Kondo N, Farrell ML, Dienstag J, Cosimi AB, Semigran MJ. Cardiovascular complications following liver transplantation. Clin Transplant 1995;9:463-471
71. Della Rocca G, Costa MG, Pompei L, Chiarandini P. The liver transplant recipient with cardiac disease. Transplant Proc 2008;40:1172-1174
72. Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004;10:1441-1453
73. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996;61:1180-1188
74. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-906
75. Park SC, Beerman LB, Gartner JC, Zitelli BJ, Malatack JJ, Fricker FJ, et al. Echocardiographic findings before and after liver transplantation. Am J Cardiol 1985;55:1373-1378
76. Nasraway SA, Klein RD, Spanier TB, Rohrer RJ, Freeman RB, Rand WM, et al. Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation: evidence for early postoperative myocardial depression. Chest 1995;107:218-224
77. Agusti AG, Roca J, Rodriguez-Roisin R, Mastai R, Wagner PD, Bosch J. Pulmonary hemodynamics and gas exchange during exercise in liver cirrhosis. Am Rev Respir Dis 1989;139:485-491 (Pubitemid 19057430)
78. Rassiat E, Barriere E, Durand F, Bernuau J, Belghiti J, Valla D, et al. Pulmonary hemodynamics and gas exchange after liver transplantation in patients with cirrhosis. Dig Dis Sci 2002;47:746-749
79. Sogni P, Garnier P, Gadano A, Moreau R, Dall'Ava-Santucci J, Dinh-Xuan AT, et al. Endogenous pulmonary nitric oxide production measured from exhaled air is increased in patients with severe cirrhosis. J Hepatol 1995;23:471-473
80. Rolla G, Brussino L, Colagrande P, Scappaticci E, Morello M, Bergerone S, et al. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med 1998;129:375-378
81. Delclaux C, Mahut B, Zerah-Lancner F, Delacourt C, Laoud S, Cherqui D, et al. Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med 2002;165:332-337
82. Zhang J, Ling Y, Luo B, Tang L, Ryter SW, Stockard CR, et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology 2003;125:1441-1451
83. Rolla G, Bucca C, Brussino L. Methylene blue in the hepatopulmonary syndrome. N Engl J Med 1994;331:1098.
84. Schenk P, Madl C, Rezaie-Majd S, Lehr S, Muller C. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000;133:701-706
85. Rolla G, Brussino L, Colagrande P, Dutto L, Polizzi S, Scappaticci E, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997;26:842-847
86. Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: A new approach. Gastroenterology 1998;114:305-310
87. Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: Hepatopulmonary syndrome. J Clin Gastroenterol 2005;39:S138-42.
88. Zhang HY, Han DW, Wang XG, Zhao YC, Zhou X, Zhao HZ. Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome. World J Gastroenterol 2005;11:567-572
89. Rabiller A, Nunes H, Lebrec D, Tazi KA, Wartski M, Dulmet E, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 2002;166:514-517
90. Krowka MJ, Tajik AJ, Dickson ER, Wiesner RH, Cortese DA. Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates: Screening by two-dimensional contrast-enhanced echocardiography. Chest 1990;97:1165-1170
91. Hedenstierna G, Soderman C, Eriksson LS, Wahren J. Ventilation- perfusion inequality in patients with non-alcoholic liver cirrhosis. Eur Respir J 1991;4:711-717
92. Ramsay MA. Portopulmonary hypertension and hepatopulmonary syndrome, and liver transplantation. Int Anesthesiol Clin 2006;44:69-82.
93. Huffmyer JL, Nemergut EC. Respiratory dysfunction and pulmonary disease in cirrhosis and other hepatic disorders. Respir Care 2007;52:1030-1036 .
94. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17:17-33.
95. Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver- lung interactions. Clin Chest Med 1996;17:151-169
96. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363:1461-1468
97. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: Morphologic and clinical features. J Am Coll Cardiol 1987;10:1233-1238
98. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-744
99. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-334
100. Davis HH 2nd, Schwartz DJ, Lefrak SS, Susman N, Schainker BA. Alveolarcapillary oxygen disequilibrium in hepatic cirrhosis. Chest 1978;73:507-511
101. Krowka MJ, Cortese DA. Hepatoplumonary syndrome: Current concepts in diagnosis and therapeutic considerations. Chest 1994;105:1528-1537
102. Krowka MJ, Cortese DA. Hepatopulmonary syndrome: An evolving perspective in the era of liver transplantation. Hepatology 1990;11:138-142
103. Hoffbauer FW, Rydell R. Multiple pulmonary arteriovenous fistulas in juvenile cirrhosis. Am J Med 1956;21:450-460
104. Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome: A liver- induced lung vascular disorder. N Engl J Med 2008;358:2378-2387
105. Ferreira MA, Barreto SS, Knorst MM, Silva MR, Pinotti AF. Semiquantitative echocardiographic evaluation of intrapulmonary vascular dilatations: Correlation with evaluation of shunt levels and pulmonary function parameters. J Bras Pneumol 2009;35:106-113
106. Swanson KL, Wiesner RH, Krowka MJ. Natural history ofhepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005;41:1122-1129
107. Lange PA, Stoller JK. The hepatopulmonary syndrome: Effect of liver transplantation. Clin Chest Med 1996;17:115-123
108. Philit F, Wiesendanger T, Gille D, Boillot O, Cordier JF. Late resolution of hepatopulmonary syndrome after liver transplantation. Respiration 1997;64:173-175
109. Mandell MS, Groves BM, Duke J. Progressive plexogenic pulmonary hypertension following liver transplantation. Transplantation 1995;59:1488-1490
110. Abrams GA, Rose K, Fallon MB, McGuire BM, Bloomer JR, van Leeuwen DJ, et al. Hepatopulmonary syndrome and venous emboli causing intracerebral hemorrhages after liver transplantation: A case report. Transplantation 1999;68:1809-1811
111. KawutSM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11:1107-1111
112. Krowka MJ. Pulmonary hypertension, (high) risk of orthotopic liver transplantation, and some lessons from "primary" pulmonary hypertension (editorial). Liver Transpl 2002;8:389-390
113. Ramsay MA. Perioperative mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:451-452
114. Al-Hamoudi W, Alqahtani S, Ma M, Lee SS. Hemodynamics in the immediate postoperative period after liver transplantation in alcoholic and postviral cirrhosis. Can J Gastroenterol 2007;21:S029.
115. Glauser FL. Systemic hemodynamics and cardiac function changes in patients undergoing orthotropic liver transplantation. Chest 1990;98:1210-1215
116. Navasa M, Feu F, Garcia-Pagan JC, Jimenez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993;17:355-360 (Pubitemid 23072807)
117. Henderson JM, Mackay GJ, Hooks M, Chezmar JL, GallowayJR, Dodson TF, et al. High cardiac output of advanced liver disease persists after orthotropic liver transplantation. Hepatology 1992;15:258-262
118. Gadano A, Hadengue A, Widmann J, Vachiery F, Moreau R, Yang S, et al. Hemodynamics after orthotropic liver transplantation: Study of associated factors and long-term effects. Hepatology 1995;22:458-465